Related Experiment Video
Updated: Aug 18, 2026

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
Published on: June 6, 2025
[Low dosages of tricyclic antidepressants]
A M van Hemert1, T K Birkenhäger
1Parnassia Psycho-medisch Centrum, Bureau 24-uurszorg, Avocadostraat 2, 2552 HS Den Haag.
Abstract:
In a meta-analysis of 39 controlled studies, tricyclic antidepressants (TCAs) were found to be effective in the treatment of depressive disorders at dosages under 100 mg/day. No advantage was found for the generally recommended higher dosages. However, the authors ofthe analysis did not pay attention to the problems of diagnostic and therapeutic heterogeneity in the studies that were included. After a closer look, it seems plausible that TCAs do have an effect at lower dosages. Due to the diagnostic heterogeneity, however, it remains unclear whether the effect is on the core symptoms of depressive disorders or rather on symptoms such as anxiety, pain or sleep disorders. Due to the therapeutic heterogeneity, no claims with regard to the effectiveness of lower dosages are justified. The meta-analysis provides no reason to adjust the current guidelines for the dosage of TCAs in the treatment of depressive disorders.
Related Concept Videos
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Antidepressant Drugs: MAOIs and Other Agents
Antidepressant Drugs: Overview
Drug Therapy
Antianxiety Medications
Drugs Affecting Neurotransmitter Release or Uptake
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...